A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
Researchers at Oak Ridge National Laboratory have developed a method of adding nanostructures to high-entropy metal alloys, or HEAs, that enhance both strength and ductility, which is the ability to deform or stretch
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
Matthew Ryder has been named an emerging investigator by the American Chemical Society journal Crystal Growth and Design. The ACS recognized him as “one of an emerging generation of research group leaders for his work on porous materials design.”
A team led by the ORNL has found a rare quantum material in which electrons move in coordinated ways, essentially “dancing.”
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.